Dr. Johnson discusses the FDA's April 2026 update to the epcoritamab label permitting outpatient monitoring for the first full 48 mg dose in relapsed/refractory DLBCL.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
